Standard BioTools Inc. Stock price

Equities

LAB

US34385P1084

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 11:02:02 2024-03-28 am EDT 5-day change 1st Jan Change
2.705 USD +0.56% Intraday chart for Standard BioTools Inc. +0.37% +22.62%
Sales 2024 * 200M Sales 2025 * 235M Capitalization 1.03B
Net income 2024 * -161M Net income 2025 * -69M EV / Sales 2024 * 5.15 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 4.38 x
P/E ratio 2024 *
-4.8 x
P/E ratio 2025 *
-11.2 x
Employees 537
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.56%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.89%
1 week+2.67%
Current month+19.56%
1 month+14.96%
3 months+22.27%
6 months-5.94%
Current year+21.72%
More quotes
1 week
2.63
Extreme 2.63
2.78
1 month
2.23
Extreme 2.23
2.91
Current year
1.74
Extreme 1.735
2.91
1 year
1.46
Extreme 1.46
3.16
3 years
0.92
Extreme 0.92
7.51
5 years
0.92
Extreme 0.92
14.30
10 years
0.92
Extreme 0.92
46.38
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 22-04-03
Director of Finance/CFO 55 23-05-14
Chief Tech/Sci/R&D Officer - Jan. 04
Members of the board TitleAgeSince
Director/Board Member 70 22-03-31
Director/Board Member 66 23-03-14
Director/Board Member 60 Jan. 04
More insiders
Date Price Change Volume
24-03-28 2.71 +0.74% 215 250
24-03-27 2.69 +1.89% 1,444,933
24-03-26 2.64 -2.22% 1,702,867
24-03-25 2.7 +0.75% 1,474,455
24-03-22 2.68 -0.74% 1,872,940

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. Its segments include Proteomics and Genomics. Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. It provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company distributes its systems through its direct sales force and support organizations.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.69 USD
Average target price
4 USD
Spread / Average Target
+48.70%
Consensus
  1. Stock
  2. Equities
  3. Stock Standard BioTools Inc. - Nasdaq